Vitrolife (Q4 initial take): Aligned nicely with estimates - Redeye

Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and a significant reported EBIT loss driven by the goodwill impairment announced in December. Accordingly, our view of the investment case remains intact, and we anticipate limited to no estimate revisions, alongside a modest share price reaction.

Länk till analysen i sin helhet: https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates?utm_source=finwire&utm_medium=RSS